Antirapsyn Antibodies in Chronic Procainamide‐associated Myopathy (CPAM)

Agius, Mark; Zhu, Shuyu; Fairclough, Robert H.

doi:10.1111/j.1749-6632.1998.tb10975.x

Cited by 5 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pathogenesis may be related to lupus-like vasculitis, which can occur in patients treated with procainamide. In one study Antirapsyn antibodies were reported in chronic procainamide-associated myopathy (82). The myopathy resolves following withdrawal of procainamide.…”

Section: Drug Induced Inflammatory Myopathiesmentioning

confidence: 99%

Toxic Myopathies

2014

View full text Add to dashboard Cite

Muscle tissue is highly sensitive to many substances. Early recognition of toxic myopathies is important, as they potentially are reversible on removal of the offending drug or toxin, with greater likelihood of complete resolution the sooner this is achieved. Clinical features range from mild muscle pain and cramps to severe weakness with rhabdomyolysis, renal failure, and even death. The pathogenic bases can be multifactorial. This article reviews some of the common toxic myopathies and their clinical presentation, histopathologic features and possible underlying cellular mechanisms.

show abstract

Section: Drug Induced Inflammatory Myopathiesmentioning

confidence: 99%

Toxic Myopathies

2014

View full text Add to dashboard Cite

show abstract

“…Rapsyn is an intracellular scaffold protein located in the muscle cells, which connects the AChR to the cytoskeleton inside the cell. Although 15% of MG patients had Rapsyn antibodies in their serum, they could be present in the serum of patients with other diseases [34][35][36]. Similar to this, the antibody against cortactin is found in 23.7% of SNMG patients, 9.5% of seropositive MG, 12.5% of patients with other autoimmune diseases, 7.6-26% of skin disorders (polymyositis, dermatomyositis, and immune-mediated necrotizing myopathy), and 5.2% of healthy controls [37][38][39][40].…”

Section: Immunologic Biomarkers Of Mgmentioning

confidence: 99%

Overview of biomarkers in myasthenia gravis

Afrashteh

Rajabi

2022

Explor Neuroprot Ther

View full text Add to dashboard Cite

Myasthenia gravis (MG) is a rare auto-immune neuromuscular junction (NMJ) disorder which is caused by formation of autoantibodies and destruction of NMJ components. The MG diagnosis is based on the symptoms, autoantibodies detection and paraclinical tests. Given that MG patients have so many differential diagnosis and various medication responses, choosing an accurate diagnosis and the therapy plan in MG is challenging. According to the studies, there are the immunologic, genetic, microRNAs, gut microbiome, and other established or newly proposed biomarkers for diagnosis and prognosis of MG. More studies are needed to provide better collection of biomarkers in MG patients and evaluate their role in MG pathology.

show abstract

“…Procainamide can also rarely cause a myopathy (Sayler and DeJong, 1991;Venkayya et al, 1993;Agius et al, 1998). The creatine phosphokinase (CPK) levels in procainamide-induced myopathy can be normal or greater than 10 000 IU per liter (Meschia and Biller, 1998).…”

Section: Antiarrhythmicsmentioning

confidence: 99%